GLUE
Monte Rosa Therapeutics Inc
$5.8
Earnings Summary
Revenue | $0Mn |
Net Profits | $-33.25Mn |
Net Profit Margins | -Inf% |
Highlights
Monte Rosa Therapeutics Inc’s revenue jumped NaN% since last year same period to $0Mn in the Q4 2023. On a quarterly growth basis, Monte Rosa Therapeutics Inc has generated NaN% jump in its revenue since last 3-months.
Monte Rosa Therapeutics Inc’s net profit fell -14.37% since last year same period to $-33.25Mn in the Q4 2023. On a quarterly growth basis, Monte Rosa Therapeutics Inc has generated 4.68% jump in its net profits since last 3-months.
Monte Rosa Therapeutics Inc’s net profit margin jumped NaN% since last year same period to -Inf% in the Q4 2023. On a quarterly growth basis, Monte Rosa Therapeutics Inc has generated NaN% jump in its net profit margins since last 3-months.
Earnings per share (EPS) Estimates
Earnings per share (EPS) estimates of the Monte Rosa Therapeutics Inc post its latest quarter earnings
EPS Estimate Current Quarter | -0.65 |
EPS Estimate Current Year | -0.65 |
Highlights
Monte Rosa Therapeutics Inc’s earning per share (EPS) estimates for the current quarter stand at -0.65 - a -95.67% fall from last quarter’s estimates.
Monte Rosa Therapeutics Inc’s earning per share (EPS) estimates for the current year stand at -0.65.
Key Ratios
Key ratios of the Monte Rosa Therapeutics Inc post its Q1 2024 earnings
Earning Per Share (EPS) | 0 |
Highlights
Monte Rosa Therapeutics Inc’s earning per share (EPS) jumped 100% since last year same period to 0 in the Q1 2024. This indicates that the Monte Rosa Therapeutics Inc has generated 100% annual rate of jump in its earning per share (EPS) in the last 4 quarters.
Earnings Calendar
| Earnings Date | Estimated EPS | Reported EPS | Surprise % |
|---|---|---|---|
2024-05-09 | -0.65 | 0 | 100% |
₹0 US Stocks a/c Opening Fee